Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges.

Glennon J, Purper-Ouakil D, Bakker M, Zuddas A, Hoekstra P, Schulze U, Castro-Fornieles J, Santosh PJ, Arango C, Kölch M, Coghill D, Flamarique I, Penzol MJ, Wan M, Murray M, Wong IC, Danckaerts M, Bonnot O, Falissard B, Masi G, Fegert JM, Vicari S, Carucci S, Dittmann RW, Buitelaar JK; PERS Consortium..

Eur Child Adolesc Psychiatry. 2014 Dec;23(12):1149-60. doi: 10.1007/s00787-013-0498-3. Epub 2013 Dec 15.

2.

Topiramate versus Valproate Sodium as Adjunctive Therapies to a Combination of Lithium and Risperidone for Adolescents with Bipolar I Disorder: Effects on Weight and Serum Lipid Profiles.

Mahmoudi-Gharaei J, Shahrivar Z, Faghihi T, Mohammadi MR, Tehrani-Doost M, Alaghband-Rad J, Ghaeli P.

Iran J Psychiatry. 2012 Winter;7(1):1-10.

3.

Obesity and psychotic disorders: uncovering common mechanisms through metabolomics.

Oresic M.

Dis Model Mech. 2012 Sep;5(5):614-20. doi: 10.1242/dmm.009845. Review.

4.

Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth.

Pringsheim T, Panagiotopoulos C, Davidson J, Ho J; CAMESA guideline group..

J Can Acad Child Adolesc Psychiatry. 2011 Aug;20(3):218-33. Erratum in: J Can Acad Child Adolesc Psychiatry. 2011 August;20(3):1–2..

5.

Trichotillomania and its treatment: a review and recommendations.

Franklin ME, Zagrabbe K, Benavides KL.

Expert Rev Neurother. 2011 Aug;11(8):1165-74. doi: 10.1586/ern.11.93. Review.

6.

Some effects of risperidone and quetiapine on growth parameters and hormone levels in young pigtail macaques.

Sackett G, Unis A, Crouthamel B.

J Child Adolesc Psychopharmacol. 2010 Dec;20(6):489-93. doi: 10.1089/cap.2010.0018.

7.

Relationships between the use of second-generation antipsychotics and changes in total cholesterol levels in children and adolescents perinatally infected with HIV.

Kapetanovic S, Aaron L, Williams PL, Farley J, Sirois PA, Garvie PA, Pearson DA, Oleske JM, Montepiedra G; The IMPAACT PACTG 219C Team..

Neurobehav HIV Med. 2010 Aug;2010(2):39-48.

8.

First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents.

Panagiotopoulos C, Ronsley R, Elbe D, Davidson J, Smith DH.

J Can Acad Child Adolesc Psychiatry. 2010 May;19(2):124-37.

9.

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.

Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK.

JAMA. 2009 Oct 28;302(16):1765-73. doi: 10.1001/jama.2009.1549. Erratum in: JAMA. 2009 Dec 2;302(21):2322.

10.

The use of second-generation antipsychotics and the changes in physical growth in children and adolescents with perinatally acquired HIV.

Kapetanovic S, Aaron L, Montepiedra G, Sirois PA, Oleske JM, Malee K, Pearson DA, Nichols SL, Garvie PA, Farley J, Nozyce ML, Mintz M, Williams PL; Pediatric AIDS Clinical Trials..

AIDS Patient Care STDS. 2009 Nov;23(11):939-47. doi: 10.1089/apc.2009.0121.

11.

The role of pharmacotherapy in the management of self-regulation difficulties in young children.

Reebye PN, Elbe D.

J Can Acad Child Adolesc Psychiatry. 2009 May;18(2):150-9.

Supplemental Content

Support Center